Evidence map›Paper›PMID 39680260›Full record

ArticleClinical rheumatology2025

Low serum S100A6 levels are associated RP-ILD risk in anti-MDA5-positive dermatomyositis.

Wei Yan, Qin Wu, Yumeng Shi, Hanxiao You, Jieting Jia, Defang Meng, Li Ma, Xuexiang Zhang, Xindi Yu, Wenfeng Tan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wei YanDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Qin WuDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Yumeng ShiDivision of Rheumatology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Hanxiao YouDivision of Rheumatology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Jieting JiaDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Defang MengDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Li MaDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Xuexiang ZhangDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Xindi YuDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China.
Wenfeng TanDivision of Rheumatology, The First Affiliated Hospital With Nanjing Medical University, Nanjing, China.
Hua WeiDivision of Rheumatology, Northern Jiangsu People's Hospital, Jiangsu, China. yzweihua2018@163.com.ORCID http://orcid.org/0000-0001-6241-9868

Funding

National Natural Science Foundation of China 82101878Northern Jiangsu People's Hospital SBKY21006
6 · The paper itself

Abstract

introductionAnti-MDA5-positive dermatomyositis (anti-MDA5-DM) is a rare autoimmune disease that often leads to rapid-progressive interstitial lung disease (RP-ILD). The lack of effective prediction and treatment methods makes RP-ILD a major risk factor for death in patients with this condition. S100A6 is a member of the S100 Ca2 + - binding protein family, which plays important roles in inflammation, tumor, injury, and fibroblast reparation. This study aims to explore the correlation between serum S100A6 and RP-ILD in anti-MDA5-DM, and to determine whether S100A6 can be used as a specific biomarker to predict RP-ILD.

methodsThe authors enrolled 80 participants, including 20 healthy volunteers, 20 patients with anti-synthase syndrome, and 40 patients with anti-MDA5-positive dermatomyositis. Serum samples were collected and the levels of S100A6 were measured using ELISA. Logistic regression was used to analyze the relationship between serum S100A6 levels and RP-ILD, along with other clinical and laboratory parameters. 

resultsSerum S100A6 levels were significantly lower in anti-MDA5-DM patients with RP-ILD than those without RP-ILD (odds ratio:0.393 (95% CI, 0.164-0.943, p = 0.036)). High serum S100A6 level was found to be a protective factor for RP-ILD. This study shows that high serum S100A6 level may be a protective factor for RP-ILD in anti-MDA5-DM patients. Serum S100A6 may be used as a specific biomarker to predict whether RP-ILD occurs in anti-MDA5-DM. Key Points • This research discovers and reports a biomarker (S100A6) for distinguishing potential RP-ILD in Anti-MDA5 positive dermatomyositis.

Indexed as

DermatomyositisInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialS100 Calcium Binding Protein A6AdultAgedAutoantibodiesBiomarkersCase-Control StudiesCell Cycle ProteinsFemaleHumansMaleMiddle AgedRisk FactorsAutoantibodiesBiomarkersCell Cycle ProteinsIFIH1 protein, humanInterferon-Induced Helicase, IFIH1S100A6 protein, humanS100 Calcium Binding Protein A6DermatomyositisMDA5S100A6

Identifiers

PMID39680260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.